MS Project

ARTICLE

All questions refer to the "Case Study" which is posted in the Assignments section in Blackboard. Read the case and answer all the questions.

Please answer in full sentences. Use the information provided in the case as a basis for your answer. You may include other information or knowledge, but make sure your answer is based first on the information in the case. Make sure to reference concepts discussed in class or the textbook in your answers. Remember, you must cite anything that is not your own thoughts or words.

FORMATTING COUNTS! BREAK UP YOUR ANSWERS INTO LOGICAL PARAGRAPHS WITH BLANK LINES BETWEEN PARAGRAPHS TO MAKE IT EASY TO READ. DO NOT ANSWER IN ONE LONG PARAGRAPH WITH NO SPACES OR YOU WILL LOSE MARKS FOR FORMATTING. YOU MUST USE APA Guidelines.

This is an Individual Assignment.

Introduction and Instructions:

Bridging the gap between heart failure and a transplant

For some of the 26 million people with heart failure, a transplant is the best optionwhich can mean waiting years for a donor. French medical device maker Carmat has been working on a solution since its founding in 2008, finally unveiling Aeson, an artificial heart that can replace the whole organ for up to six months.

Patients have traditionally had limited options. SynCardia was the first artificial heart to be approved in Europe and the only one that has U.S. Food and Drug Administration approval for sale in the United States. By offering another option, Carmat has the potential to bridge a massive gap: Among the 1.3 million people with advanced-stage heart disease, only 5,500 receive a transplant each year.

Collaborating with technological experts from Airbus Group, Carmat developed the units lining from preserved bovine pericardium tissue, which has been used for heart valve replacement and can help reduce the risk of blood clots or strokes in implant patients. The team also designed the unit to be self-adjusting. And because the team incorporated pressure sensors into the device, Aeson can automatically regulate blood flow, reducing the need for patients to meet with doctors for post-implant adjustments.

Carmat conducted its first test implant in 2013 and has since iterated improvements on Aeson and the battery pack that powers it to provide patients what the company calls "a near-normal life." The European Union approved the device in December 2020, and in July, surgeons completed the first implants in patients in Italy, Germany and the United States. As the company continues to ramp up production and build up inventories to scale the device across Europe and the United States, Carmat CEO Stphane Piat said the projects initial results "makes us very confident that our Aeson artificial heart is a gamechanger."

Carmat is now in extended negotiations with various service providers and given the urgency of the launch is revising its schedule baseline. The Project Director is planning on involving students from select institutions in this initiative as part of their Co-op. Therefore, students from MAN 400 are asked to convert the information given below into a schedule baseline in MS Project which will lead to creating the schedule baseline for Aeson.

Create a Project Schedule using the table below. Please pay attention to these points:

1. Project Start date is 1-Jan-2022
2. All activities are clearly and properly labeled
3. The relationship between the activities is properly represented
4. Duration of the activities are accurate
5. Critical Path highlighted and it is correct
6. Project End date is correct
7. Assign Resources
8. Set up Milestones
9. Schedule baseline is uploaded on Blackboard in both .mpp and .pdf format

Customized Connecting Software
Activity	Task	Preceding Activity	Activity Time (Work Weeks)
A	Requirement Gathering	No preceding activity	10
B	Resource Onboarding	A	5
C	Valve Design	A	20
D	Valve Development	B	15
E	Valve Calibration	C	50
F	Implant Testing	C	15
G	Battery Pack Testing	D	35
H	Integration Testing	E, F, G	15